


# functional Insulin-like Growth Factor Binding Protein-3 LIA E04A\*


The main physiological function of IGF-Binding Proteins is the regulation of bioavailability of IGF-I and -II. IGF-I forms a ternary complex with the acid-labile subunit and IGFBP-3 from which it can be released selectively by **proteolytical cleavage**. Therefore the cleavage products of the proteolysis also appear in serum besides the intact IGFBP-3.

## Do you know what you are measuring?

The plot of total-IGFBP-3 values against functional IGFBP-3 shows that **25 %** of the determined total-IGFBP-3 is not functional.




The part of intact IGFBP-3 is reduced by e.g. **tumor- and liver diseases** as well as by **growth disorders**.



The proteolysis of IGFBP-3 is changed during several physiological conditions:

- **Tumors**
- **Catabolic States**
- **Burns**
- **Pregnancy**



A clear gender difference was obvious in the relative part of functional IGFBP-3 by comparison of healthy **men and women**:

	Total IGFBP-3; min/max(ng/ml)	Funct. IGFBP-3; min/max(ng/ml)	Functional IGFBP-3 (% of total)
females	3568; 1752/5752	2506; 1102/4346	70,2
males	2752; 1258/4726	2332; 1337/4304	84,8
overall	3160	2419	77,5

### Assay - Characteristics

Performance like ELISA Protocol – very fast & simple

- ✓ small sample requirement, thus ideal for **paediatric patients**
- ✓ no cross reactions
- ✓ direct correlation to total-IGFBP-3 (the same sample dilution can be used)
- ✓ IGF-I binding IGFBP-3 is detected only
- ✓ analytical sensitivity of 0.18 ng/ml
- ✓ wide linear range
- ✓ 5 single standards (0.4 -30 ng/ml))
- ✓ Intra-Assay Variance < 5,6%
- ✓ Inter-Assay Variance < 6,8%
- ✓ rapid assay procedure: **Incubation 3.5h**

\* Patent pending DE19719001

## Mediagnost functional IGFBP-3 LIA E04A

<b>Reconstitution/ Dilution of Reagents:</b>		
<b>Standards A-E</b>	Reconstitution in <b>Sample Buffer PP</b> (green)	<b>1 ml each</b>
<b>Control Seren KS1 &amp; KS2</b>	Reconstitution in <b>Sample Buffer PP</b> (green)	<b>250 µl</b>
<b>Ligand Conjugate LK</b>	Dilute LK and EK 1:101 each in <b>Dilution Buffer VP</b> (e.g. <b>60 µl LK</b> plus <b>6 ml VP</b> each)	<b>1:101 each</b>
<b>Enzyme Conjugate EK</b>	(e.g. <b>120 µl EK</b> plus <b>12 ml VP</b> each)	
<b>Washing Buffer WP</b>	dilute in <b>A. dest.</b> (e.g. add the complete contents of the flask 50 ml into a graduated flask and fill with A.dest. to 1000 ml)	<b>1:20</b>
<b>Sample Dilution + Control Sera KS1 &amp; KS2: 1:505 in Sample Buffer PP</b> (green colored), <b>mix directly and use within max. 60 min.</b>		
Use <b>50 µl per determination</b> (pipetting control= blue coloration)		
Before assay procedure bring all <b>reagents</b> to <b>room temperature</b>		

### Proposal of Assay Procedure for Double Determination:

Pipette	Reagents	Well Positions
50 µl	<b>diluted Ligand Conjugate LK</b>	Pipette in <u>all</u> required number of wells
50 µl	Sample Buffer <b>PP</b> as Blank	A1 and A2
50 µl	Standard <b>A (0.4 ng/ml)</b>	B1 and B2
50 µl	Standard <b>B (2 ng/ml)</b>	C1 and C2
50 µl	Standard <b>C (6 ng/ml)</b>	D1 and D2
50 µl	Standard <b>D (15 ng/ml)</b>	E1 and E2
50 µl	Standard <b>E (30 ng/ml)</b>	F1 and F2
50 µl	diluted Control Serum <b>KS1</b>	G1 and G2
50 µl	diluted Control Serum <b>KS2</b>	H1 and H2
50 µl	<b>diluted Samples</b>	Pipette samples in the rest of the wells according to requirements
Cover the wells with the sealing tape		

#### Incubation: 2 h at RT, 350 rpm

5x 300 µl	Aspirate the contents of the wells and wash <b>5x</b> with <b>300 µl</b> each <b>WP/ well</b>	each well
100 µl	diluted Enzyme Conjugate <b>EK</b>	each well

#### Incubation: 1 h at RT, 350 rpm

5x 300 µl	Aspirate the contents of the wells and wash <b>5x</b> with <b>300 µl</b> each <b>WP/ well</b>	each well
100 µl	Substrate Solution <b>S</b>	each well

#### Incubation: 30 min in the dark at RT

100 µl	Stop Solution <b>SL</b>	each well
Measure the absorbance within 30 min at <b>450 nm</b> (≥590 nm Reference)		